Next Generation Medicine: Specialty Drug Costs, Data & Supply Chain
The latest specialty drug cost management levers that employers and plan sponsors are considering to deliver meaningful cost savings and improved patient outcomes.
Specialty drugs accounted for an estimated 40%-50% of drug spend in 2020. An influx of new gene therapies has an expected sales forecast of $16 billion in 2024.
At the same time, clinical advancements have allowed for the creation of cures and treatments for a number of chronic illnesses and previously untreatable diseases.
Watch the panel discussion from The Council’s Employee Benefits Leadership Forum, which examines contracting strategies, plan design and personalized medicine.
Chris Crawford, Chief Growth Officer, Vivio Health
Joshua Fredell, PharmD, Vice President, Product Development, CVS Health
Laura Jester, Senior Director, Specialty/Pharmacy Solutions, Navitus Health Solutions
Scott Musial, Chief Pharmacy Officer, Rightway Healthcare
Moderated by: Ryan Rice, Principal & Practice Leader, Prism Health Strategists